Genomic landscape of acquired resistance to targeted therapies in metastatic colorectal cancer (mCRC).

被引：0
|
作者：
Harrold, Emily
Keane, Fergus
Sinopoli, Jenna Cohen
Diaz, Luis A.
Cercek, Andrea
Yaeger, Rona
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, GME Off, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
190
引用
收藏
页码：190 / 190
页数：1
相关论文
共 50 条
  • [31] Personalized approach to the selection of standard and targeted therapies in metastatic colorectal cancer
    Engel, R.
    Boka, H.
    Archer, S.
    Nguyen, S.
    Nickless, D.
    Niap, A.
    Plazzer, J. P.
    Georges, C.
    Fennell, L.
    Skinner, L.
    Mcmurrick, P.
    Abud, H.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 32 - 33
  • [32] Efficacy of Targeted Therapies in Metastatic Colorectal Cancer: Meta-Analysis
    Gouverneur, Amandine
    Arnaud, Mickael
    Berdai, Driss
    DeBoissieu, Paul
    Fourrier-Reglat, Annie
    Noize, Pernelle
    Salvo, Francesco
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 363 - 364
  • [33] Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence
    Gonzalo Tapia Rico
    Amanda R. Townsend
    Vy Broadbridge
    Timothy J. Price
    Drugs & Aging, 2017, 34 : 173 - 189
  • [34] Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer
    Sartore-Bianchi, A.
    Bencardino, K.
    Cassingena, A.
    Venturini, F.
    Funaioli, C.
    Cipani, T.
    Amatu, A.
    Pietrogiovanna, L.
    Schiavo, R.
    Di Nicolantonio, F.
    Artale, S.
    Bardelli, A.
    Siena, S.
    CANCER TREATMENT REVIEWS, 2010, 36 : S1 - S5
  • [35] Comorbidities in patients with metastatic colorectal cancer (mCRC)
    Fu, A. Z.
    Zhao, Z.
    Wang, P. F.
    Barber, B.
    Liu, G. G.
    EJC SUPPLEMENTS, 2009, 7 (02): : 339 - 339
  • [36] INTENSIVE CHEMOTHERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
    Ychou, M.
    ANNALS OF ONCOLOGY, 2013, 24
  • [37] Microsatellite instability in metastatic colorectal cancer (mCRC)
    Kim, Jee Hung
    Kim, Chang-gon
    Ahn, Joong Bae
    Jung, MinKyu
    Beom, Seung Hoon
    Kim, Joo Hoon
    Heo, Soo Jin
    Shin, Sang Joon
    CANCER RESEARCH, 2016, 76
  • [38] Temporospatial heterogeneity in metastatic colorectal cancer (mCRC)
    Fountzilas, C.
    Witkiewicz, A.
    Muhitch, J.
    Abrams, S.
    Knudsen, E.
    Mukherjee, S.
    Bajor, D.
    Saltzman, J.
    Wang, K.
    Iyer, R.
    Kalinski, P.
    Boland, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1458 - S1458
  • [39] Genomic alterations associated with resistance to EGFR monoclonal antibodies (mAb) in real-world patients with metastatic colorectal cancer (mCRC).
    Klempner, Samuel J.
    Quintanilha, Julia C. F. C. F.
    Emmett, Matthew
    Graf, Ryon
    Schrock, Alexa Betzig
    Tukachinsky, Hanna
    Oxnard, Geoffrey R.
    Myer, Parvathi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 52 - 52
  • [40] Identification of a novel predictive genomic biomarker for response to combination bevacizumab in metastatic colorectal cancer (mCRC).
    Byrne, Annette T.
    Smeets, Dominiek
    Miller, Ian S.
    Das, Sudipto
    Boeckx, Bram
    Depreeuw, Jeroen
    Gaiser, Timo
    Betge, Johannes
    Barat, Ana
    Murphy, Verena
    Moran, Bruce
    Fender, Bozena
    Klinger, Rut
    Ebert, Matthias Philip
    van Grieken, Nicole C. T.
    Ylstra, Bauke
    Gallagher, William M.
    Prehn, Jochen
    O'Connor, Darran
    Lambrechts, Diether
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345